Audience shot
Late-breaking science| Achieving equity in prevention
Nov 15th, 2023
audience shot
Novel mechanisms for lipid-lowering therapy
Nov 14th, 2023
LBS 08 panelists
Late-breaking science: AI at the bedside
Nov 14th, 2023
Lbs05 Panel Web
Shocking decisions in AFib care
Nov 13th, 2023
Lbs04 Panel2 Web
Drugs, diet and delivery can optimize hypertension outcomes
Nov 13th, 2023
audience shot
Heart failure late-breaking science
Nov 13th, 2023
A. Michael Lincoff, MD
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
Nov 12th, 2023
From left: Christopher Rajkumar, MD, MRC, Jeffrey L. Carson, MD, MACP; Stefan James, MD.
Trials’ results suggest new approaches to reducing CVD risk and symptoms
Nov 12th, 2023
AHA audience
Late-Breaking Science announced
Sep 21st, 2023
audience
Early ablation bests medication in treatment naïve AFib patients
Nov 9th, 2022
audience shot
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
Nov 9th, 2022
audience shot
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
Nov 8th, 2022